FATE THERAPEUTICS INC Defined Contribution Plan, Cost
FATE THERAPEUTICS INC (FATE) reported Defined Contribution Plan, Cost of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2023-02-28
- FATE THERAPEUTICS INC defined contribution plan, cost for fiscal 2022 was $0.00.
- FATE THERAPEUTICS INC defined contribution plan, cost for fiscal 2021 was $0.00.
- FATE THERAPEUTICS INC defined contribution plan, cost for fiscal 2020 was $0.00.
- FATE THERAPEUTICS INC defined contribution plan, cost for fiscal 2019 was $0.00.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-24 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-05 |
| 2017-12-31 | $0.00 10-K · filed 2018-03-05 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-16 |
| 2015-12-31 | $0.00 10-K · filed 2016-03-03 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-12 |
| 2013-12-31 | $0.00 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |